Literature DB >> 18625856

Distinct pools of beta-amyloid in Alzheimer disease-affected brain: a clinicopathologic study.

Joshua R Steinerman1, Michael Irizarry, Nikolaos Scarmeas, Susan Raju, Jason Brandt, Marilyn Albert, Deborah Blacker, Bradley Hyman, Yaakov Stern.   

Abstract

OBJECTIVE: To determine whether beta-amyloid (Abeta) peptides segregated into distinct biochemical compartments would differentially correlate with clinical severity of Alzheimer disease (AD).
DESIGN: Clinicopathologic correlation study. PARTICIPANTS: Twenty-seven patients from a longitudinal study of AD and 13 age- and sex-matched controls without a known history of cognitive impairment or dementia were included in this study.
INTERVENTIONS: Temporal and cingulate neocortex were processed using a 4-step extraction, yielding biochemical fractions that are hypothesized to be enriched with proteins from distinct anatomical compartments: TRIS (extracellular soluble), Triton (intracellular soluble), sodium dodecyl sulfate (SDS) (membrane associated), and formic acid (extracellular insoluble). Levels of Abeta(40) and Abeta(42) were quantified in each biochemical compartment by enzyme-linked immunosorbent assay.
RESULTS: The Abeta(42) level in all biochemical compartments was significantly elevated in patients with AD vs controls (P < .01). The Abeta(40) levels in the TRIS and formic acid fractions were elevated in patients with AD (temporal, P < .01; cingulate, P = .03); however, Triton and SDS Abeta(40) levels were similar in patients with AD and in controls. Functional impairment proximal to death correlated with Triton Abeta(42) (r = 0.48, P = .02) and SDS Abeta(42) (r = 0.41, P = .04) in the temporal cortex. Faster cognitive decline was associated with elevated temporal SDS Abeta(42) levels (P < .001), whereas slower decline was associated with elevated cingulate formic acid Abeta(42) and SDS Abeta(42) levels (P = .02 and P = .01, respectively).
CONCLUSION: Intracellular and membrane-associated Abeta, especially Abeta(42) in the temporal neocortex, may be more closely related to AD symptoms than other measured Abeta species.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625856      PMCID: PMC2586606          DOI: 10.1001/archneur.65.7.906

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  36 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease.

Authors:  P Giannakopoulos; F R Herrmann; T Bussière; C Bouras; E Kövari; D P Perl; J H Morrison; G Gold; P R Hof
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

3.  Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology.

Authors:  Reisuke H Takahashi; Teresa A Milner; Feng Li; Ellen E Nam; Mark A Edgar; Haruyasu Yamaguchi; M Flint Beal; Huaxi Xu; Paul Greengard; Gunnar K Gouras
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline.

Authors:  J Näslund; V Haroutunian; R Mohs; K L Davis; P Davies; P Greengard; J D Buxbaum
Journal:  JAMA       Date:  2000 Mar 22-29       Impact factor: 56.272

5.  Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome.

Authors:  K A Gyure; R Durham; W F Stewart; J E Smialek; J C Troncoso
Journal:  Arch Pathol Lab Med       Date:  2001-04       Impact factor: 5.534

6.  The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain.

Authors:  D M Walsh; B P Tseng; R E Rydel; M B Podlisny; D J Selkoe
Journal:  Biochemistry       Date:  2000-09-05       Impact factor: 3.162

7.  Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease.

Authors:  Hiroaki Fukumoto; Bonnie S Cheung; Bradley T Hyman; Michael C Irizarry
Journal:  Arch Neurol       Date:  2002-09

Review 8.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

9.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

10.  Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss.

Authors:  Yuesong Gong; Lei Chang; Kirsten L Viola; Pascale N Lacor; Mary P Lambert; Caleb E Finch; Grant A Krafft; William L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

View more
  42 in total

1.  Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Authors:  Gaëlle Naert; Serge Rivest
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

2.  Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines.

Authors:  Viorela Pop; Elizabeth Head; Nicole C Berchtold; Charles G Glabe; Christa M Studzinski; Adam M Weidner; M Paul Murphy; Carl W Cotman
Journal:  Neurobiol Aging       Date:  2010-04-30       Impact factor: 4.673

3.  PAK inactivation impairs social recognition in 3xTg-AD Mice without increasing brain deposition of tau and Aβ.

Authors:  Dany Arsenault; Alexandre Dal-Pan; Cyntia Tremblay; David A Bennett; Matthieu J Guitton; Yves De Koninck; Susumu Tonegawa; Frédéric Calon
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

4.  Chronic Sleep Restriction Induces Cognitive Deficits and Cortical Beta-Amyloid Deposition in Mice via BACE1-Antisense Activation.

Authors:  Hong-Yi Zhao; Hui-Juan Wu; Jia-Lin He; Jian-Hua Zhuang; Zhen-Yu Liu; Liu-Qing Huang; Zhong-Xin Zhao
Journal:  CNS Neurosci Ther       Date:  2017-02-01       Impact factor: 5.243

Review 5.  Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.

Authors:  Varsha Shukla; Susan Skuntz; Harish C Pant
Journal:  Arch Med Res       Date:  2012-11-07       Impact factor: 2.235

6.  Multifunctional liposomes reduce brain β-amyloid burden and ameliorate memory impairment in Alzheimer's disease mouse models.

Authors:  Claudia Balducci; Simona Mancini; Stefania Minniti; Pietro La Vitola; Margherita Zotti; Giulio Sancini; Mario Mauri; Alfredo Cagnotto; Laura Colombo; Fabio Fiordaliso; Emanuele Grigoli; Mario Salmona; Anniina Snellman; Merja Haaparanta-Solin; Gianluigi Forloni; Massimo Masserini; Francesca Re
Journal:  J Neurosci       Date:  2014-10-15       Impact factor: 6.167

Review 7.  Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease.

Authors:  Gunnar K Gouras; Davide Tampellini; Reisuke H Takahashi; Estibaliz Capetillo-Zarate
Journal:  Acta Neuropathol       Date:  2010-03-31       Impact factor: 17.088

8.  A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and In Vivo Efficacy and Molecular Mechanisms.

Authors:  Jeffrey S Derrick; Richard A Kerr; Younwoo Nam; Shin Bi Oh; Hyuck Jin Lee; Kaylin G Earnest; Nayoung Suh; Kristy L Peck; Mehmet Ozbil; Kyle J Korshavn; Ayyalusamy Ramamoorthy; Rajeev Prabhakar; Edward J Merino; Jason Shearer; Joo-Yong Lee; Brandon T Ruotolo; Mi Hee Lim
Journal:  J Am Chem Soc       Date:  2015-11-17       Impact factor: 15.419

9.  Mixed oligomers and monomeric amyloid-β disrupts endothelial cells integrity and reduces monomeric amyloid-β transport across hCMEC/D3 cell line as an in vitro blood-brain barrier model.

Authors:  Hisham Qosa; Harry LeVine; Jeffrey N Keller; Amal Kaddoumi
Journal:  Biochim Biophys Acta       Date:  2014-07-02

Review 10.  Recent advances in our understanding of neurodegeneration.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2009-06-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.